BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38515208)

  • 21. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.
    Clarke CA; Keegan TH; Yang J; Press DJ; Kurian AW; Patel AH; Lacey JV
    J Natl Cancer Inst; 2012 Jul; 104(14):1094-101. PubMed ID: 22773826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
    Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
    Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival.
    Roseland ME; Schwartz K; Ruterbusch JJ; Lamerato L; Krajenta R; Booza J; Simon MS
    Breast Cancer Res Treat; 2017 Aug; 165(1):163-168. PubMed ID: 28547656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neighborhood disadvantage and individual-level life stressors in relation to breast cancer incidence in US Black women.
    Barber LE; Zirpoli GR; Cozier YC; Rosenberg L; Petrick JL; Bertrand KA; Palmer JR
    Breast Cancer Res; 2021 Nov; 23(1):108. PubMed ID: 34809694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
    Liu Y; West R; Weber JD; Colditz GA
    Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
    Lin NU; Vanderplas A; Hughes ME; Theriault RL; Edge SB; Wong YN; Blayney DW; Niland JC; Winer EP; Weeks JC
    Cancer; 2012 Nov; 118(22):5463-72. PubMed ID: 22544643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
    Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
    J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study.
    Conway K; Edmiston SN; Tse CK; Bryant C; Kuan PF; Hair BY; Parrish EA; May R; Swift-Scanlan T
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):921-30. PubMed ID: 25809865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
    Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
    J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas.
    Huo D; Hu H; Rhie SK; Gamazon ER; Cherniack AD; Liu J; Yoshimatsu TF; Pitt JJ; Hoadley KA; Troester M; Ru Y; Lichtenberg T; Sturtz LA; Shelley CS; Benz CC; Mills GB; Laird PW; Shriver CD; Perou CM; Olopade OI
    JAMA Oncol; 2017 Dec; 3(12):1654-1662. PubMed ID: 28472234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 as a marker of prognosis in African-American women with breast cancer.
    Dookeran KA; Dignam JJ; Ferrer K; Sekosan M; McCaskill-Stevens W; Gehlert S
    Ann Surg Oncol; 2010 May; 17(5):1398-405. PubMed ID: 20049641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
    Hoskins KF; Danciu OC; Ko NY; Calip GS
    JAMA Oncol; 2021 Mar; 7(3):370-378. PubMed ID: 33475714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.
    Keenan T; Moy B; Mroz EA; Ross K; Niemierko A; Rocco JW; Isakoff S; Ellisen LW; Bardia A
    J Clin Oncol; 2015 Nov; 33(31):3621-7. PubMed ID: 26371147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Racial disparities in breast carcinoma survival rates: seperating factors that affect diagnosis from factors that affect treatment.
    Chu KC; Lamar CA; Freeman HP
    Cancer; 2003 Jun; 97(11):2853-60. PubMed ID: 12767100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
    Elledge RM; Clark GM; Chamness GC; Osborne CK
    J Natl Cancer Inst; 1994 May; 86(9):705-12. PubMed ID: 7908990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
    JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Racial differences in CD8
    Abdou Y; Attwood K; Cheng TD; Yao S; Bandera EV; Zirpoli GR; Ondracek RP; Stein L; Bshara W; Khoury T; Ambrosone CB; Omilian AR
    Breast Cancer Res; 2020 Jun; 22(1):62. PubMed ID: 32517730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pan-cancer analysis identifies BIRC5 as a prognostic biomarker.
    Fäldt Beding A; Larsson P; Helou K; Einbeigi Z; Parris TZ
    BMC Cancer; 2022 Mar; 22(1):322. PubMed ID: 35331169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
    Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
    Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.